Rancho Santa Fe, CA, United States of America

Stephen M Coutts

This inventor holds 14 USPTO granted patents. Top assignees: La Jolla Pharmaceutical Company, Euro-Celtique S.a., La Jolla Pharmaceutial Company. Active years: 1990-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen M Coutts. Retrieved from https://idiyas.com/inventor/stephen-m-coutts

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14

% Patents Active = 85.7

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 248(Granted Patents)

Location History:

Rancho Sante Fe, CA (US) (1999)
Rancho Santa Fe, CA (US) (1990 - 2000)
San Diego, CA (US) (1994 - 2008)

Company Filing History:

11 out of 42

La Jolla Pharmaceutical Company

La Jolla Pharmaceutial Company

patent

Years Active: 1990-2008

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7351855 - Chemically defined non-polymeric valency platform molecules and conjugates thereof (2008-04-01),

2. 7115581 - Chemically-defined non-polymeric valency platform molecules and conjugates thereof (2006-10-03),

3. 6060056 - Composition for inducing humoral anergy to an immunogen comprising a T (2000-05-09),

4. 5874552 - Modified phosphorous intermediates for providing functional groups on (1999-02-23),

5. 5786512 - Modified phosphorous intermediates for providing functional groups on (1998-07-28),

6. 5726329 - Modified phosphorous intermediates for providing functional groups on (1998-03-10),

7. 5633395 - Chemically-defined non-polymeric valency platform molecules and (1997-05-27),

8. 5606047 - Chemically-defined non-polymeric valency platform molecules and (1997-02-25),

9. 5552391 - Chemically-defined non-polymeric valency platform molecules and (1996-09-03),

10. 5391785 - Intermediates for providing functional groups on the 5' end of (1995-02-21),

11. 5276013 - Conjugates of biologically stable polyfunctional molecules and (1994-01-04),

12. 5162515 - Conjugates of biologically stable polymers and polynucleotides for (1992-11-10),

13. 5019573 - Substituted dibenzofurans and methods of using same (1991-05-28),

14. 4956371 - Substituted isoquinolines and methods of using same (1990-09-11),

Title: The Innovative Contributions of Stephen M Coutts

Introduction

Stephen M Coutts is a prominent inventor based in Rancho Santa Fe, California. He holds an impressive portfolio of 14 patents, showcasing his significant contributions to the field of biotechnology. His work primarily focuses on the development of chemically defined non-polymeric valency platform molecules, which have important applications in medical research.

Latest Patents

Coutts' latest patents include groundbreaking innovations such as "Chemically defined non-polymeric valency platform molecules and conjugates thereof." This patent describes chemically-defined, non-polymeric valency platform molecules and conjugates that comprise biologically or chemically relevant molecules, including polynucleotide duplexes of at least 20 base pairs. These molecules exhibit significant binding activity for human lupus anti-dsDNA autoantibodies, highlighting their potential in therapeutic applications.

Career Highlights

Throughout his career, Coutts has worked with notable companies, including La Jolla Pharmaceutical Company and Euro-Celtique S.A. His experience in these organizations has allowed him to refine his expertise and contribute to innovative projects that advance the field of biotechnology.

Collaborations

Coutts has collaborated with esteemed colleagues such as David S Jones and Douglas Alan Livingston. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of cutting-edge technologies.

Conclusion

Stephen M Coutts is a distinguished inventor whose work in the field of biotechnology has led to significant advancements. His patents and collaborations reflect his commitment to innovation and the pursuit of solutions for complex medical challenges.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]